Sharechat Logo

Caldera says third study of PSA-test alternative shows high ability to spot Prostate cancer

Thursday 15th September 2016

Text too small?

Caldera Health, a New Zealand biotech company working on a gene-sequencing replacement for the world’s most widely used prostate cancer test, says its third clinical test has shown a strong ability to identify prostate cancer and screen out those who test negative.

The company is working on a replacement for the widely used PSA blood test with a simple “pee in a pot” test, using RNA biomarkers. In 2012, the US Preventive Services Task Force recommended against mass PSA screening because it threw up both false positives and negatives, didn't distinguish between aggressive cancers and benign strains or even other prostate conditions, and led to over-diagnosis and unnecessary prostatectomies.

The company says its clinical study 2B was completed in July with 157 samples analysed using the gene signatures developed in its earlier clinical study 2. The study will be bulked out with another 100 or so samples, it said.

The 'panel of genes' could identify prostate cancer "with a sensitivity of 96 percent (percentage of patients with disease who test positive) and a specificity of 99 percent (percentage of patients without disease who test negative)," Caldera said in a statement. "This result is significantly more accurate than the PSA-antigen blood test."

The company is now developing a prostate cell capture device that can isolate the prostate cells away from other cells present in the urine. "We will then apply our accurate gene signature that we have developed. We hope to finalise our proof in principle devices before the year's end and a prototype early 2017."

A proof-of-principle device will then be extensively tested with a larger number of clinical samples, followed by the development of a clinic-ready system that could be introduced and used in clinical practice, it said.

After that, "we will seek a partner in the form of an established multi-national diagnostic company that has the resources required to take the device through the regulatory pathways before ultimately bringing it to the market". Caldera "needs ongoing investment from angel investors, venture capital firms and a partner in order to get to this point".

Caldera Health conducted its first trial last year, using stored prostatectomy tissue from men who had had their prostate bladders removed. Watt said live tissues are also needed to help test the biomarkers for the gene sequencing.

Investors so far include the NZ Venture Investment Fund, the Mercy Ascot Health group, and Stephen Tindall’s K1W1 investment company.

BusinessDesk.co.nz



  General Finance Advertising    

Comments from our readers

No comments yet

Add your comment:
Your name:
Your email:
Not displayed to the public
Comment:
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Related News:

SML - Synlait Milk Limited - Trading Halt of Securities
AIA - Auckland Airport announces board chair changes
AIA - Auckland Airport announces board chair changes
CEN - Tauhara commissioning progress update
FPH initiates voluntary limited recall
March 28th Morning Report
KFL Celebrates 20 Years of Excellence in Investment Mgmt.
SVR - Savor FY24 Earnings Guidance & Change in Banking Partner
NZK - NZ King Salmon Investments Limited FY24 Results
March 27th Morning Report